Arbli Patent Expiration

Arbli is a drug owned by Scienture Llc. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 07, 2041. Details of Arbli's patents and their expiration are given in the table below.

Filter patents by

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12156869 Losartan liquid formulations and methods of use
Oct, 2041

(16 years from now)

Active
US11890273 Losartan liquid formulations and methods of use
Oct, 2041

(16 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Arbli is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Arbli's family patents as well as insights into ongoing legal events on those patents.

Arbli's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Arbli's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 07, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Arbli Generic API suppliers:

Losartan Potassium is the generic name for the brand Arbli. 24 different companies have already filed for the generic of Arbli, with Aiping Pharm Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Arbli's generic





About Arbli

Arbli is a drug owned by Scienture Llc. Arbli uses Losartan Potassium as an active ingredient. Arbli was launched by Scienture in 2025.

Approval Date:

Arbli was approved by FDA for market use on 13 March, 2025.

Active Ingredient:

Arbli uses Losartan Potassium as the active ingredient. Check out other Drugs and Companies using Losartan Potassium ingredient

Dosage:

Arbli is available in suspension form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
10MG/ML SUSPENSION Prescription ORAL